

CIF A-18.758.300  
Avda. de la Innovación, n 1  
Edificio BIC (Ofic. 211)  
P. T. de Ciencias de la Salud  
18100 Armilla (Granada)  
**Tel: 958 750 598**

Mercado Alternativo Bursátil  
Plaza de la Lealtad, 1  
28014 Madrid

In Granada, 30 October 2014

## RELEVANT FACT OF NEURON BIO

Dear Sirs,

In compliance with the provisions of the MAB circular 9/2010 on information to be provided by the companies in expansion integrated in the MAB the company, Neuron Bio, S.A. (hereinafter "NEURON BIO" or the "Company"), hereby puts in knowledge the following information.

The European Patent Office (EPO) has granted Neuron Bio with the patent "Use of statins as anticonvulsants, antiepileptics and neuroprotectors" that has been published in the Spanish Official Bulletin of Industrial Property with number EP2301532B1.

The patent protects the new chemical entity NST0037 and its use for the prevention and treatment of neurodegenerative diseases, cognitive impairment and pathological processes linked to age.

This is the first patent granted to Neuron Bio by the European Patent Office and it might enable the company to reach marketing agreements with third parties for the use of simvastatin as an antiepileptic drug in Europe. The simvastatin is a known drug, commonly used to treat high cholesterol, something that might allow carrying out directly clinical assays in phase II (clinical proof of concept in humans) for the new patented indication.

We remain at your disposal for any clarification you consider appropriate.

Kind regards,

Fernando Valdivieso Amate  
Chairman of the Board of Directors